Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

ar mortality rates versus warfarin: the incidence was 3.17% for warfarin, 2.74% (p=0.013) for the edoxaban 60 mg treatment arm and 2.71% (p=0.008) for the edoxaban 30 mg treatment arm. The primary net clinical outcome (defined in the study protocol as the composite of death, stroke, SEE or major bleeding) was 8.11% per year for warfarin, 7.26% per year for the edoxaban 60 mg treatment arm (p=0.003) and 6.79% per year for the edoxaban 30 mg treatment arm (p<0.001).2

About ENGAGE AF-TIMI 48

ENGAGE AF-TIMI 48 (Effective aNticoaGulation with Factor XA next GEneration in Atrial Fibrillation) was a three-arm, randomized, double-blind, double-dummy, global phase 3 clinical trial comparing once-daily edoxaban with warfarin in 21,105 patients with NVAF at moderate-to-high risk of thromboembolic events at 1,393 centers in 46 countries.2

Patients were randomized (1:1:1) to receive warfarin (n=7,036), edoxaban 60 mg (n=7,035) or edoxaban 30 mg (n=7,034). Edoxaban dosage was reduced by half if any of the following was present at randomization or during the course of the study: creatinine clearance 30-50 mL/min, body-weight < or = 60 kg, or concomitant verapamil, quinidine or dronedarone (standard dosing was resumed if the concomitant drug was discontinued and no other dose reduction factors were present). The primary efficacy outcome was the time to first adjudicated stroke or SEE. The principal safety outcome was adjudicated major bleeding. Complete information on the primary endpoint was ascertained for 99.5% of the total 56,346 patient-years of potential follow-up, with only one patient lost to follow-up. Warfarin therapy was proactively monitored throughout the trial, resulting in a median time within therapeutic range (TTR) of 68.4%. Adverse event (excluding bleeding) and discontinuation rates were similar among the three treatment groups.2

ENGAGE AF-TIMI 48 implemented a unique, pre-specified plan to trans
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015 Cord Blood America, Inc. ( www.cordblood-america.com ... the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, with ... and provides an update for shareholders detailing why a "YES" ... Dear Shareholders, As we reflect upon ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
Breaking Medicine Technology:Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
(Date:1/22/2015)... U.S. Pharmacopeial Convention is pleased to announce that Gigi ... North Carolina State’s College of Veterinary Medicine has been ... Distinguished Volunteer Service—the organization’s highest award. , Since ... experts to direct its work to improve the health ...
(Date:1/22/2015)... Hollywood, California (PRWEB) January 22, 2015 The City ... 2015 at 10 a.m., to commemorate the 42nd anniversary of the ... United States. , “It’s been 42 years since the Roe vs. ... choose is still as present as ever,” said City of West ...
(Date:1/22/2015)... AZ (PRWEB) January 22, 2015 Padre Murphy's ... long supporter of Pro Player Health Alliance (PPHA). ... Padre Murphy's in getting everyone, including NFL greats, treated for ... of the leading groups supporting the cause in the valley. ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
Breaking Medicine News(10 mins):Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 2Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 3Health News:Gigi Davidson, Pioneer in Veterinary Pharmacy and Leader in Pharmacy Compounding, honored with USP’s Beal Award for Dedication to Public Health 4Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4
... of doctors and their patients with diabetes do not see ... manage, according to a survey by the University of Michigan ... and hypertension among their top concerns, 38 percent of doctors ... while only 18 percent of diabetics said it was the ...
... ... a distribution agreement to provide GuardRFID’s Active RFID platform to its Healthcare, Government and ... ... with VT Milcom of Virginia Beach, Va. to provide its next generation RFID platform ...
... , ... Feb. 2 Hospitals in the Boston area ... (ICUs) prevent central-line bloodstream infections, a cause of death, disability, and ... February 2 , www.ConsumerReportsHealth.org will post hospital infection rates ...
... , RANCHO CORDOVA, Calif. , ... the delivery of eyecare and eyewear through innovative business solutions ... Jr. as its chief financial officer. Ball will replace ... recently retired after 31 years, and report to chief executive ...
... ... Hospitals in Los Angeles vary dramatically in terms ... a cause of death, disability, and expense in our nations, hospitals that ... post hospital infection rates for 41 Los Angeles area hospitals, ...
... ... patient safety information in the public eye , YONKERS, N.Y. ... Tampa / St. Petersburg area vary dramatically in terms of how ... of death, disability, and expense in our nations, hospitals that is largely ...
Cached Medicine News:Health News:Diabetes patients rank health concerns differently than their doctors, U-M survey shows 2Health News:Guard RFID Solutions Inc. and VT Milcom Enter into Distribution Agreement 2Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates In Boston Hospitals Vary Dramatically; Some Hospitals Not Reporting 7Health News:VSP Global Appoints New Chief Financial Officer 2Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 2Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 3Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 4Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 5Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 6Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 7Health News:Consumer Reports Health: Central-Line Infection Rates in Los Angeles Hospitals Vary Dramatically; Some Hospitals Not Reporting 8Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 2Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 3Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 4Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 5Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 6
For the quantitative determination of uric acid in serum....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... A fully automated, random ... over 50 assays available ... tumor marker, therapeutic drug, ... testing can be performed ...
Medicine Products: